Security key
45719W205
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)
CUSIP: 45719W205
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 140,000,283
- Total 13F shares
- 429,662
- Share change
- -317,476
- Total reported value
- $597,627
- Price per share
- $1.39
- Number of holders
- 13
- Value change
- -$496,803
- Number of buys
- 9
- Number of sells
- 5
Report period
Q3 2023
Institutions
13
Top holders
10
IKT full security history
Newer quarter: Q4 2023
Previous quarter: Q2 2023
Inhibikase Therapeutics, Inc. SEC filings
Inhibikase Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45719W205
Recent filing periods:
Top shareholders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.35%
|
496,547
|
$1,792,535 | — | 30 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.06%
|
88,310
|
$318,799 | — | 30 Jun 2023 | |
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
0.04%
|
57,888
|
$208,976 | — | 30 Jun 2023 | |
| Redmond Asset Management, LLC |
13F
|
Company |
0.01%
|
20,976
|
$75,723 | — | 30 Jun 2023 | |
| EDGEWOOD MANAGEMENT LLC |
13F
|
Company |
0.01%
|
16,667
|
$60,167 | — | 30 Jun 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.01%
|
14,840
|
$51,643 | — | 30 Jun 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.01%
|
12,722
|
$46,000 | — | 30 Jun 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
11,455
|
$41,353 | — | 30 Jun 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.01%
|
10,082
|
$35,085 | — | 30 Jun 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,984
|
$7,162 | — | 30 Jun 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,667
|
$6,018 | — | 30 Jun 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
196
|
$707 | — | 30 Jun 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
2
|
$7 | — | 30 Jun 2023 | |
| HAMILTON LANE ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
27,604
mixed-class rows
|
$99,825 | — | 30 Jun 2023 | |
| Joseph Frattaroli |
3/4/5
|
Cheif Financial Officer |
—
mixed-class rows
|
138,091
mixed-class rows
|
$38,473 | — | 01 Mar 2023 | |
| Elizabeth G. O'Farrell |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 24 Jun 2022 |
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q3 2023
As of 30 Sep 2023,
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
429,662 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, BLAIR WILLIAM & CO/IL, GEODE CAPITAL MANAGEMENT, LLC, Redmond Asset Management, LLC, EDGEWOOD MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, Tower Research Capital LLC (TRC), and MORGAN STANLEY.
This page lists
13
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
14
Q3 2023 holders
13
Holder diff
-1
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.